Peripheral T cell lymphoma: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
(6 intermediate revisions by the same user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{SI}}                                                                 
{{SI}}                                                                 
{{CMG}}
 
{{CMG}}  
==Overview==
==Overview==
The peripheral T-cell lymphomas (PTCLs) consists of  a heterogeneous group of aggressive diseases that constitutes ~10%-15% of non Hodgkin lymphoma. The incidence has been estimated to be <1 case per 100,000 of ppl in United states.  <ref name="Morton2006">{{cite journal|last1=Morton|first1=L. M.|title=Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001|journal=Blood|volume=107|issue=1|year=2006|pages=265–276|issn=0006-4971|doi=10.1182/blood-2005-06-2508}}</ref>The most common type is Peripheral T cell lymphoma, not otherwise specified (PTCL, NOS), followed by Anaplastic large cell lymphoma, primary systemic type (ALCL) , Angioimmunoblastic T cell lymphoma (AITL) and Extranodal NK/T cell lymphoma, nasal type (PTCLs ), which is the rarest type. Although each type presents differently and has special histological features, they all have similar treatment . In addition, all the types have been associated with poor prognosis. <ref name="MoskowitzLunning2014">{{cite journal|last1=Moskowitz|first1=A. J.|last2=Lunning|first2=M. A.|last3=Horwitz|first3=S. M.|title=How I treat the peripheral T-cell lymphomas|journal=Blood|volume=123|issue=17|year=2014|pages=2636–2644|issn=0006-4971|doi=10.1182/blood-2013-12-516245}}</ref> The most common presentation is generalized lymphadenopathy with or without extra nodal manifestations. <ref>{{cite journal|doi=10.1182/blood-2010-09-310342.}}</ref>
The peripheral T-cell lymphomas (PTCLs) consists of  a heterogeneous group of aggressive diseases that constitutes ~10%-15% of non Hodgkin lymphoma. The incidence has been estimated to be <1 case per 100,000 of ppl in United states.  <ref name="Morton2006">{{cite journal|last1=Morton|first1=L. M.|title=Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001|journal=Blood|volume=107|issue=1|year=2006|pages=265–276|issn=0006-4971|doi=10.1182/blood-2005-06-2508}}</ref>The most common type is Peripheral T cell lymphoma, not otherwise specified (PTCL, NOS), followed by Anaplastic large cell lymphoma, primary systemic type (ALCL) , Angioimmunoblastic T cell lymphoma (AITL) and Extranodal NK/T cell lymphoma, nasal type (PTCLs ), which is the rarest type. Although each type presents differently and has special histological features, they all have similar treatment . In addition, all the types have been associated with poor prognosis. <ref name="MoskowitzLunning2014">{{cite journal|last1=Moskowitz|first1=A. J.|last2=Lunning|first2=M. A.|last3=Horwitz|first3=S. M.|title=How I treat the peripheral T-cell lymphomas|journal=Blood|volume=123|issue=17|year=2014|pages=2636–2644|issn=0006-4971|doi=10.1182/blood-2013-12-516245}}</ref> The most common presentation is generalized lymphadenopathy with or without extra nodal manifestations. <ref>{{cite journal|doi=10.1182/blood-2010-09-310342.}}</ref>  
 
==Historical Perspective==
*[Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
*In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
*In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].
==Classification==
*
clinical trials.


== Classification ==
== Classification ==
In 2008, WHO classified peripheral T cell lymphoma in 4 groups ( cutaneous, nodal, extra nodal and leukemic)  based on their clinical manifestations .   
In 2008, WHO classified peripheral T cell lymphoma in 4 groups ( cutaneous, nodal, extra nodal and leukemic)  based on their clinical manifestations .[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519704/table/tbl0005/?report=objectonly]  


In which the  majority of  aggressive T-cell lymphomas have been included in the nodal, extranodal, and leukemic groups.  
In which the  majority of  aggressive T-cell lymphomas have been included in the nodal, extranodal, and leukemic groups.  
Line 44: Line 36:


==Pathophysiology==
==Pathophysiology==
*The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
Recently three key mechanisms of peripheral T cell transformation have been demonstrated in different studies, including" (a) the deregulation of signaling pathways controlling T cell development, differentiation, and maturation; (b) the remodeling of the peritumor microenvironment; and (c) the virus-mediated rewiring of T cell biology."<ref name="PizziMargolskee2018">{{cite journal|last1=Pizzi|first1=Marco|last2=Margolskee|first2=Elizabeth|last3=Inghirami|first3=Giorgio|title=Pathogenesis of Peripheral T Cell Lymphoma|journal=Annual Review of Pathology: Mechanisms of Disease|volume=13|issue=1|year=2018|pages=293–320|issn=1553-4006|doi=10.1146/annurev-pathol-020117-043821}}</ref>
*The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
 
*On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
==Clinical Features==
*On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
Depending on the subtypes, clinical manifestations may vary however, the majority of patients  present with generalized lymphadenopathy with or without extranodal disease <ref name="pmid18626005">{{cite journal| author=Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project| title=International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. | journal=J Clin Oncol | year= 2008 | volume= 26 | issue= 25 | pages= 4124-30 | pmid=18626005 | doi=10.1200/JCO.2008.16.4558 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18626005  }}</ref>.  Having nodal disease alone is seen in around 38% of patients, 49% present with both nodal and extranodal disease, while around 13% only present with extranodal disease <ref name="pmid21270441">{{cite journal| author=Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA et al.| title=Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. | journal=Blood | year= 2011 | volume= 117 | issue= 12 | pages= 3402-8 | pmid=21270441 | doi=10.1182/blood-2010-09-310342 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21270441  }}</ref>. Hepatomegaly is seen in 17% and splenomegaly in 24% of patients. The bone marrow involvement is seen in 20%. Some patients present with eosinophilia, pruritus<ref name="pmid2153036">{{cite journal| author=Falini B, Pileri S, De Solas I, Martelli MF, Mason DY, Delsol G et al.| title=Peripheral T-cell lymphoma associated with hemophagocytic syndrome. | journal=Blood | year= 1990 | volume= 75 | issue= 2 | pages= 434-44 | pmid=2153036 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2153036  }}</ref>].  In 1/4 of cases, thrombocytopenia and anemia are seen. <ref name="pmid212704412">{{cite journal| author=Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA et al.| title=Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. | journal=Blood | year= 2011 | volume= 117 | issue= 12 | pages= 3402-8 | pmid=21270441 | doi=10.1182/blood-2010-09-310342 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21270441  }}</ref>


==Clinical Features==   
Extranodal sites involved are mainly skin and gastrointestinal tract  <ref name="pmid1466400">{{cite journal| author=Chott A, Dragosics B, Radaszkiewicz T| title=Peripheral T-cell lymphomas of the intestine. | journal=Am J Pathol | year= 1992 | volume= 141 | issue= 6 | pages= 1361-71 | pmid=1466400 | doi= | pmc=1886751 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1466400  }}</ref>. Fever, night sweats and weight loss which are typical systemic B symptoms ,are reported in 35% of cases <ref name="pmid212704413">{{cite journal| author=Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA et al.| title=Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. | journal=Blood | year= 2011 | volume= 117 | issue= 12 | pages= 3402-8 | pmid=21270441 | doi=10.1182/blood-2010-09-310342 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21270441 }}</ref>. 50% of patients have increased LDH level and 14% of cases are associated with hypergammaglobulinemia.


==Differentiating [disease name] from other Diseases==
==The distinction between subtypes of Peripheral T cell Lymphoma and with other [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3953129/table/T1/?report=objectonly diseases]==
*[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
*·        AITL tumor cells have typical morphological characteristics which are absent in PTCL, NOS . AITL, tumor cells express CD10, BCL6, PD1, or CXCL13 as well as mutations in DNMT3A, TET2, IDH2, and RHOG which is not the case in PTCL, NOS<ref name="pmid26980727">{{cite journal| author=Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al.| title=The 2016 revision of the World Health Organization classification of lymphoid neoplasms. | journal=Blood | year= 2016 | volume= 127 | issue= 20 | pages= 2375-90 | pmid=26980727 | doi=10.1182/blood-2016-01-643569 | pmc=4874220 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26980727  }}</ref> <ref name="pmid24413734">{{cite journal| author=Palomero T, Couronné L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A et al.| title=Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. | journal=Nat Genet | year= 2014 | volume= 46 | issue= 2 | pages= 166-70 | pmid=24413734 | doi=10.1038/ng.2873 | pmc=3963408 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24413734  }}</ref>, Differential diagnosis of peripheral T cell lymphoma are other T cell lymphomas and B cell lymphomas  that share common morphologic and/or immunophenotypic characteristics, and  disorders  such as hypersensitivity reactions and prolonged or robust immune responses to viral infections which can cause hyperplasia of nodal paracortical T cell zones.
:*[Differential dx1]
:*[Differential dx2]
:*[Differential dx3]
   
==Epidemiology and Demographics==
==Epidemiology and Demographics==
* The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
* The incidence of PTCL is < 1 case per 100 000 people in the United States.<ref name="Morton20062">{{cite journal|last1=Morton|first1=L. M.|title=Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001|journal=Blood|volume=107|issue=1|year=2006|pages=265–276|issn=0006-4971|doi=10.1182/blood-2005-06-2508}}</ref> The most common subtypes are the nodal T-cell lymphomas, with PTCL-NOS (25.9%) followed by AITLs (18.5%) and the ALCLs (12%). NK-/T-cell lymphomas (10.4%), while enteropathy-associated T-cell lymphomas (4.7%), hepatosplenic T-cell lymphomas (1.4%), and panniculitis-like T-cell lymphomas (0.9%) .  
* In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].
   
   
===Age===
===Gender and age===
*Patients of all age groups may develop [disease name].
*NK-cell nasal and nasal-type lymphomas is more common in males than in females.<ref name="FossZinzani2011">{{cite journal|last1=Foss|first1=F. M.|last2=Zinzani|first2=P. L.|last3=Vose|first3=J. M.|last4=Gascoyne|first4=R. D.|last5=Rosen|first5=S. T.|last6=Tobinai|first6=K.|title=Peripheral T-cell lymphoma|journal=Blood|volume=117|issue=25|year=2011|pages=6756–6767|issn=0006-4971|doi=10.1182/blood-2010-05-231548}}</ref> individuals older than 60 years are commonly affected although it can happen at any age during adulthood.
*[Disease name] is more commonly observed among patients aged [age range] years old.
*[Disease name] is more commonly observed among [elderly patients/young patients/children].
===Gender===
*[Disease name] affects men and women equally.
*[Gender 1] are more commonly affected with [disease name] than [gender 2].
* The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.
   
   
===Race===
===Race===
*There is no racial predilection for [disease name].
*PTCL-NOS is more common in North America and less common in the European and Asian countries; AITL is more common in Europe than in Asia or North America; ALK+ ALCL is more common in North America; ALK− ALCL is slightly more common in Europe; and the NK-/T-cell lymphomas and ATL are more common in Asia.<ref name="SavageHarris2008">{{cite journal|last1=Savage|first1=K. J.|last2=Harris|first2=N. L.|last3=Vose|first3=J. M.|last4=Ullrich|first4=F.|last5=Jaffe|first5=E. S.|last6=Connors|first6=J. M.|last7=Rimsza|first7=L.|last8=Pileri|first8=S. A.|last9=Chhanabhai|first9=M.|last10=Gascoyne|first10=R. D.|last11=Armitage|first11=J. O.|last12=Weisenburger|first12=D. D.|title=ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project|journal=Blood|volume=111|issue=12|year=2008|pages=5496–5504|issn=0006-4971|doi=10.1182/blood-2008-01-134270}}</ref> The EBV-associated lymphoproliferative, T-cell, and NK-cell neoplasms are seen mainly in Japan, Korea, and Northern China, but also in Native American populations from Central and South America. NK-cell nasal and nasal-type lymphomas is more commonly reported in Asia and Latin America<ref name="FossZinzani20112">{{cite journal|last1=Foss|first1=F. M.|last2=Zinzani|first2=P. L.|last3=Vose|first3=J. M.|last4=Gascoyne|first4=R. D.|last5=Rosen|first5=S. T.|last6=Tobinai|first6=K.|title=Peripheral T-cell lymphoma|journal=Blood|volume=117|issue=25|year=2011|pages=6756–6767|issn=0006-4971|doi=10.1182/blood-2010-05-231548}}</ref>
   
   
*[Disease name] usually affects individuals of the [race 1] race.
==Diagnosis==
*[Race 2] individuals are less likely to develop [disease name].
==Risk Factors==
*Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
== Natural History, Complications and Prognosis==
*The majority of patients with [disease name] remain asymptomatic for [duration/years].
*Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
*If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
*Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
*Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].
 
== Diagnosis ==
===Diagnostic Criteria===
===Diagnostic Criteria===
*The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
*The diagnosis made based upon the results of a tissue biopsy (usually lymph node biopsy) that demonstrates evidence of a T cell lymphoma in addition to immunophenotyping with markers mentioned in the classification section<ref name="LageCabral2015">{{cite journal|last1=Lage|first1=Luis Alberto de Pádua Covas|last2=Cabral|first2=Tamara Carvalho dos Santos|last3=Costa|first3=Renata de Oliveira|last4=Gonçalves|first4=Marianne de Castro|last5=Levy|first5=Debora|last6=Zerbini|first6=Maria Cláudia Nogueira|last7=Pereira|first7=Juliana|title=Primary nodal peripheral T-cell lymphomas: diagnosis and therapeutic considerations|journal=Revista Brasileira de Hematologia e Hemoterapia|volume=37|issue=4|year=2015|pages=277–284|issn=15168484|doi=10.1016/j.bjhh.2015.03.017}}</ref>. [[:File:PTCL NOS.jpg]]  
:*[criterion 1]
:*[criterion 2]
:*[criterion 3]
:*[criterion 4]
=== Symptoms ===
*[Disease name] is usually asymptomatic.
*Symptoms of [disease name] may include the following:
:*[symptom 1]
:*[symptom 2]
:*[symptom 3]
:*[symptom 4]
:*[symptom 5]
:*[symptom 6]
=== Physical Examination ===
*Patients with [disease name] usually appear [general appearance].
*Physical examination may be remarkable for:
:*[finding 1]
:*[finding 2]
:*[finding 3]
:*[finding 4]
:*[finding 5]
:*[finding 6]
 
=== Laboratory Findings ===
=== Laboratory Findings ===
*There are no specific laboratory findings associated with [disease name].
*Complete blood count with differential (CBC), chemistry with liver and renal function and electrolytes, lactate dehydrogenase (LDH), hepatitis B, HIV, and uric acid.  
 
*A  [positive/negative] [test name] is diagnostic of [disease name].
*An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
*Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
===Imaging Findings===
===Imaging Findings===
*There are no [imaging study] findings associated with [disease name].
*A contrast-enhanced computed tomography (CT) scan of the chest, abdomen, and pelvis which would aid in staging . Echocardiogram or MUGA should be performed if anthracyclines are planned to be used.
*[Imaging study 1] is the imaging modality of choice for [disease name].
*On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
*[Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].
   
   
=== Other Diagnostic Studies ===
=== Other Diagnostic Studies ===
*[Disease name] may also be diagnosed using [diagnostic study name].
*Unilateral bone marrow aspiration and biopsy.
*Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].
   
   
== Treatment ==
== Treatment ==
=== Medical Therapy ===
=== Medical Therapy ===
*There is no treatment for [disease name]; the mainstay of therapy is supportive care.
The combination of chemotherapy drugs used most often is CHOP:
* cyclophosphamide (Cytoxan, Procytox)
*The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
* doxorubicin (Adriamycin)
*[Medical therapy 1] acts by [mechanism of action 1].
* vincristine (Oncovin)
*Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].
* prednisone<ref name="MoskowitzLunning20142">{{cite journal|last1=Moskowitz|first1=A. J.|last2=Lunning|first2=M. A.|last3=Horwitz|first3=S. M.|title=How I treat the peripheral T-cell lymphomas|journal=Blood|volume=123|issue=17|year=2014|pages=2636–2644|issn=0006-4971|doi=10.1182/blood-2013-12-516245}}</ref>
Sometimes the following chemotherapy drugs may be used alone:
=== Surgery ===
* fludarabine (Fludara)
*Surgery is the mainstay of therapy for [disease name].
* cladribine (Leustatin)
*[Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
* pentostatin (deoxycoformycin, Nipent)
*[Surgical procedure] can only be performed for patients with [disease stage] [disease name].
* gemcitabine (Gemzar)
Based on stage of disease, evidence based treatment has been proposed.<ref name="FossZinzani20114">{{cite journal|last1=Foss|first1=F. M.|last2=Zinzani|first2=P. L.|last3=Vose|first3=J. M.|last4=Gascoyne|first4=R. D.|last5=Rosen|first5=S. T.|last6=Tobinai|first6=K.|title=Peripheral T-cell lymphoma|journal=Blood|volume=117|issue=25|year=2011|pages=6756–6767|issn=0006-4971|doi=10.1182/blood-2010-05-231548}}</ref>
=== Prevention ===
 
*There are no primary preventive measures available for [disease name].
Early-stage with localized disease:chemotherapy followed by radiotherapy
 
*Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
All patients except for those with low IPI (International Prognostic Index ) be consolidated with ASCT.
 
Among all subtypes, ALK+ ALCL is shown to have an excellent outcome. However ALK+ patients with high IPI are the exclusions.
 
Nodal T-cell lymphomas :  CHOP-based therapy.
 
Extranodal  regimens differ according to subtypes as following:
 
Panniculitis-like T-cell lymphoma, αβ type: single-agent therapies or combination chemotherapy and have shown to have an excellent outcome.
 
γδ type:  should be treated with aggressive chemotherapy followed by transplantation as they do poorly.
 
In addition,hepatosplenic and intestinal T-cell lymphomas have a poor outcome.  
 
NK-/T-cell lymphoma patients have also do not respond well to CHOP-based regimens, and alternative regimens should be considered.
 
=== Radiation therapy ===
External beam radiation therapy is often used addition to chemotherapy. It is given to affected lymph node areas at early stages of disease,
 
=== Targeted therapy ===
If there is recurrence of disease or other aforementioned agents are ineffective, targeted therapy may be used.  
 
Including:
* alemtuzumab (Campath)
* romidepsin (Istodax)<ref name="FossZinzani20113">{{cite journal|last1=Foss|first1=F. M.|last2=Zinzani|first2=P. L.|last3=Vose|first3=J. M.|last4=Gascoyne|first4=R. D.|last5=Rosen|first5=S. T.|last6=Tobinai|first6=K.|title=Peripheral T-cell lymphoma|journal=Blood|volume=117|issue=25|year=2011|pages=6756–6767|issn=0006-4971|doi=10.1182/blood-2010-05-231548}}</ref>
 
=== Stem cell transplant ===
Stem cell transplant is offered in case of recurrence of disease or in patients who are in remission after chemotherapy..
 
== Prognosis ==
Most peripheral T cell lymphoma subtypes have a worse prognosis than that seen in typical cases of diffuse large B-cell lymphoma<ref name="FossZinzani20116">{{cite journal|last1=Foss|first1=F. M.|last2=Zinzani|first2=P. L.|last3=Vose|first3=J. M.|last4=Gascoyne|first4=R. D.|last5=Rosen|first5=S. T.|last6=Tobinai|first6=K.|title=Peripheral T-cell lymphoma|journal=Blood|volume=117|issue=25|year=2011|pages=6756–6767|issn=0006-4971|doi=10.1182/blood-2010-05-231548}}</ref>.The median overall survival for most subtypes is on average 1–3 years, with a 5-year overall survival rate of only about 30%. However patients with anaplastic large cell lymphomas that are positive for anaplastic lymphoma kinase (ALK),  have a 5-year survival rate of approximately 70% with CHOP regimen.  
 
The most popular prognostic scoring system is the prognostic index for PTCL, unspecified (PIT) : One point for each of the factors
 
●Age >60 years
 
●Increased serum lactate dehydrogenase
 
●Eastern Cooperative Oncology Group (ECOG) performance status ≥2
 
●Bone marrow involvement
 
A retrospective study showed patients with zero, one, two, or three to four of these adverse prognostic factors had five-year overall survival rates of 63, 53, 33, and 18 percent, respectively. <ref name="pmid14645001">{{cite journal| author=Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U et al.| title=Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. | journal=Blood | year= 2004 | volume= 103 | issue= 7 | pages= 2474-9 | pmid=14645001 | doi=10.1182/blood-2003-09-3080 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14645001  }}</ref>


*Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Latest revision as of 19:39, 28 November 2018

WikiDoc Resources for Peripheral T cell lymphoma

Articles

Most recent articles on Peripheral T cell lymphoma

Most cited articles on Peripheral T cell lymphoma

Review articles on Peripheral T cell lymphoma

Articles on Peripheral T cell lymphoma in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Peripheral T cell lymphoma

Images of Peripheral T cell lymphoma

Photos of Peripheral T cell lymphoma

Podcasts & MP3s on Peripheral T cell lymphoma

Videos on Peripheral T cell lymphoma

Evidence Based Medicine

Cochrane Collaboration on Peripheral T cell lymphoma

Bandolier on Peripheral T cell lymphoma

TRIP on Peripheral T cell lymphoma

Clinical Trials

Ongoing Trials on Peripheral T cell lymphoma at Clinical Trials.gov

Trial results on Peripheral T cell lymphoma

Clinical Trials on Peripheral T cell lymphoma at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Peripheral T cell lymphoma

NICE Guidance on Peripheral T cell lymphoma

NHS PRODIGY Guidance

FDA on Peripheral T cell lymphoma

CDC on Peripheral T cell lymphoma

Books

Books on Peripheral T cell lymphoma

News

Peripheral T cell lymphoma in the news

Be alerted to news on Peripheral T cell lymphoma

News trends on Peripheral T cell lymphoma

Commentary

Blogs on Peripheral T cell lymphoma

Definitions

Definitions of Peripheral T cell lymphoma

Patient Resources / Community

Patient resources on Peripheral T cell lymphoma

Discussion groups on Peripheral T cell lymphoma

Patient Handouts on Peripheral T cell lymphoma

Directions to Hospitals Treating Peripheral T cell lymphoma

Risk calculators and risk factors for Peripheral T cell lymphoma

Healthcare Provider Resources

Symptoms of Peripheral T cell lymphoma

Causes & Risk Factors for Peripheral T cell lymphoma

Diagnostic studies for Peripheral T cell lymphoma

Treatment of Peripheral T cell lymphoma

Continuing Medical Education (CME)

CME Programs on Peripheral T cell lymphoma

International

Peripheral T cell lymphoma en Espanol

Peripheral T cell lymphoma en Francais

Business

Peripheral T cell lymphoma in the Marketplace

Patents on Peripheral T cell lymphoma

Experimental / Informatics

List of terms related to Peripheral T cell lymphoma

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The peripheral T-cell lymphomas (PTCLs) consists of a heterogeneous group of aggressive diseases that constitutes ~10%-15% of non Hodgkin lymphoma. The incidence has been estimated to be <1 case per 100,000 of ppl in United states. [1]The most common type is Peripheral T cell lymphoma, not otherwise specified (PTCL, NOS), followed by Anaplastic large cell lymphoma, primary systemic type (ALCL) , Angioimmunoblastic T cell lymphoma (AITL) and Extranodal NK/T cell lymphoma, nasal type (PTCLs ), which is the rarest type. Although each type presents differently and has special histological features, they all have similar treatment . In addition, all the types have been associated with poor prognosis. [2] The most common presentation is generalized lymphadenopathy with or without extra nodal manifestations. [3]

Classification

In 2008, WHO classified peripheral T cell lymphoma in 4 groups ( cutaneous, nodal, extra nodal and leukemic) based on their clinical manifestations .[2]

In which the majority of aggressive T-cell lymphomas have been included in the nodal, extranodal, and leukemic groups.

The nodal lymphoma consists of 3 entities which include :PTCL, not otherwise specified (NOS) which is the most common subtype accounting for 25.9% of cases, [4] anaplastic large cell lymphoma (ALCL), and angioimmunoblastic T-cell lymphoma (AITL).

Anaplastic large cell lymphoma (ALCS) has two recognized sub groups: ALK+ and ALK- lymphomas. Both subtypes are morphologially and immunophenotypically similar to each other however they are different molecularly. [5]They have similar incidences (6.6% and 5.5% respectively) [6]

Angioimmunoblastic T-cell lymphoma (AITL) comprises 18.5% of cases .[7] One of its variants ,lymphoepithelioid cell variant is consists of CD8 T cells with epithelioid cells in the background which is different than other variants. [8]

Less common entities have been described in extra nodal groups. Tissue tropism has been the characterized distinguishing factor.

First subtype which comprises around 1.4% of PTCL cases [9]and almost always is reported in children and young adults [10]is Hepatosplenic γδ T-cell lymphoma. In this tumor, immature or nonactivated γδ T cells infiltrate bone marrow sinusoides and spleen and Isochromosome 7q chromosomal abnormality is present.

In second subgroup, which is hepatosplenic T-cell lymphoma has often poor prognoses with median survival of below 2 years. Patients usually present with B-symptoms and decreased cell counts. The cells express CD2, CD3 and CD7 markers and lack CD4, CD5 . while CD8 and natural killer cell markers expression are variable .

The third sub-type , Enteropathy-associated T-cell lymphoma (EATL) is more common in populations with high incidence of celiac disease and accounts for 4.7% of cases of T-cell lymphoma. Pain, weight loss, and bowel perforation are the usual clinical presentations. Two morphological variants have been recognized ; pleomorphic and monomorphic. The former group is associated with celiac disease the cells usually express CD3 and CD7 and lack CD56 expression [11]. Conversely, The latter group is often not associated with the celiac disease and express CD56. Gains at chromosome 9q33-q34 has been reported in up to 70% of cases[12].

Furthermore, the intestinal T- and NK-cell lymphomas are part of the nasal-type NK-/T-cell lymphoma[13] which have been reported in Asian countries and are associated with Epstein-Barr virus (EBV) infection .

In addition, The mucocutaneous γδ T-cell lymphomas[14],the nasal type NK-/T-cell lymphomas, and even ALCLs all can present as an intestinal lymphoma[15].

Panniculitis-like T-cell lymphomas constitute only 0.9% of PTCLs which is more common in males. The characteristic clinical presentation is subcutaneous nodules that can become necrotic .The cells express CD3 and CD8 and are CD4- .[16]

The last group,leukemia has 4 subtypes including adult T-cell lymphoma (ATL) associated with human T-lymphotropic virus type I (HTLV-1), T-cell chronic large granular lymphocytic (LGL) leukemia associated with neutropenia , aggressive NK-cell leukemia, and T-cell prolymphocytic leukemia. . NK-cell leukemia and ATL often have a poor outcome.

Other types which have been included in WHO classifications include: hydroa vacciniforme-like lymphoma, NK-cell lymphoma and systemic EBV-positive T-cell lymphoproliferative disease of childhood.

Pathophysiology

Recently three key mechanisms of peripheral T cell transformation have been demonstrated in different studies, including" (a) the deregulation of signaling pathways controlling T cell development, differentiation, and maturation; (b) the remodeling of the peritumor microenvironment; and (c) the virus-mediated rewiring of T cell biology."[17]

Clinical Features

Depending on the subtypes, clinical manifestations may vary however, the majority of patients present with generalized lymphadenopathy with or without extranodal disease [18]. Having nodal disease alone is seen in around 38% of patients, 49% present with both nodal and extranodal disease, while around 13% only present with extranodal disease [19]. Hepatomegaly is seen in 17% and splenomegaly in 24% of patients. The bone marrow involvement is seen in 20%. Some patients present with eosinophilia, pruritus[20]]. In 1/4 of cases, thrombocytopenia and anemia are seen. [21]

Extranodal sites involved are mainly skin and gastrointestinal tract [22]. Fever, night sweats and weight loss which are typical systemic B symptoms ,are reported in 35% of cases [23]. 50% of patients have increased LDH level and 14% of cases are associated with hypergammaglobulinemia.

The distinction between subtypes of Peripheral T cell Lymphoma and with other diseases

  • ·        AITL tumor cells have typical morphological characteristics which are absent in PTCL, NOS . AITL, tumor cells express CD10, BCL6, PD1, or CXCL13 as well as mutations in DNMT3A, TET2, IDH2, and RHOG which is not the case in PTCL, NOS[24] [25], Differential diagnosis of peripheral T cell lymphoma are other T cell lymphomas and B cell lymphomas that share common morphologic and/or immunophenotypic characteristics, and disorders such as hypersensitivity reactions and prolonged or robust immune responses to viral infections which can cause hyperplasia of nodal paracortical T cell zones.

Epidemiology and Demographics

  • The incidence of PTCL is < 1 case per 100 000 people in the United States.[26] The most common subtypes are the nodal T-cell lymphomas, with PTCL-NOS (25.9%) followed by AITLs (18.5%) and the ALCLs (12%). NK-/T-cell lymphomas (10.4%), while enteropathy-associated T-cell lymphomas (4.7%), hepatosplenic T-cell lymphomas (1.4%), and panniculitis-like T-cell lymphomas (0.9%) .

Gender and age

  • NK-cell nasal and nasal-type lymphomas is more common in males than in females.[27] individuals older than 60 years are commonly affected although it can happen at any age during adulthood.

Race

  • PTCL-NOS is more common in North America and less common in the European and Asian countries; AITL is more common in Europe than in Asia or North America; ALK+ ALCL is more common in North America; ALK− ALCL is slightly more common in Europe; and the NK-/T-cell lymphomas and ATL are more common in Asia.[28] The EBV-associated lymphoproliferative, T-cell, and NK-cell neoplasms are seen mainly in Japan, Korea, and Northern China, but also in Native American populations from Central and South America. NK-cell nasal and nasal-type lymphomas is more commonly reported in Asia and Latin America[29]

Diagnosis

Diagnostic Criteria

  • The diagnosis made based upon the results of a tissue biopsy (usually lymph node biopsy) that demonstrates evidence of a T cell lymphoma in addition to immunophenotyping with markers mentioned in the classification section[30]. File:PTCL NOS.jpg

Laboratory Findings

  • Complete blood count with differential (CBC), chemistry with liver and renal function and electrolytes, lactate dehydrogenase (LDH), hepatitis B, HIV, and uric acid.

Imaging Findings

  • A contrast-enhanced computed tomography (CT) scan of the chest, abdomen, and pelvis which would aid in staging . Echocardiogram or MUGA should be performed if anthracyclines are planned to be used.

Other Diagnostic Studies

  • Unilateral bone marrow aspiration and biopsy.

Treatment

Medical Therapy

The combination of chemotherapy drugs used most often is CHOP:

  • cyclophosphamide (Cytoxan, Procytox)
  • doxorubicin (Adriamycin)
  • vincristine (Oncovin)
  • prednisone[31]

Sometimes the following chemotherapy drugs may be used alone:

  • fludarabine (Fludara)
  • cladribine (Leustatin)
  • pentostatin (deoxycoformycin, Nipent)
  • gemcitabine (Gemzar)

Based on stage of disease, evidence based treatment has been proposed.[32]

Early-stage with localized disease:chemotherapy followed by radiotherapy

All patients except for those with low IPI (International Prognostic Index ) be consolidated with ASCT.

Among all subtypes, ALK+ ALCL is shown to have an excellent outcome. However ALK+ patients with high IPI are the exclusions.

Nodal T-cell lymphomas : CHOP-based therapy.

Extranodal regimens differ according to subtypes as following:

Panniculitis-like T-cell lymphoma, αβ type: single-agent therapies or combination chemotherapy and have shown to have an excellent outcome.

γδ type: should be treated with aggressive chemotherapy followed by transplantation as they do poorly.

In addition,hepatosplenic and intestinal T-cell lymphomas have a poor outcome.

NK-/T-cell lymphoma patients have also do not respond well to CHOP-based regimens, and alternative regimens should be considered.

Radiation therapy

External beam radiation therapy is often used addition to chemotherapy. It is given to affected lymph node areas at early stages of disease,

Targeted therapy

If there is recurrence of disease or other aforementioned agents are ineffective, targeted therapy may be used.

Including:

  • alemtuzumab (Campath)
  • romidepsin (Istodax)[33]

Stem cell transplant

Stem cell transplant is offered in case of recurrence of disease or in patients who are in remission after chemotherapy..

Prognosis

Most peripheral T cell lymphoma subtypes have a worse prognosis than that seen in typical cases of diffuse large B-cell lymphoma[34].The median overall survival for most subtypes is on average 1–3 years, with a 5-year overall survival rate of only about 30%. However patients with anaplastic large cell lymphomas that are positive for anaplastic lymphoma kinase (ALK), have a 5-year survival rate of approximately 70% with CHOP regimen.

The most popular prognostic scoring system is the prognostic index for PTCL, unspecified (PIT) : One point for each of the factors

●Age >60 years

●Increased serum lactate dehydrogenase

●Eastern Cooperative Oncology Group (ECOG) performance status ≥2

●Bone marrow involvement

A retrospective study showed patients with zero, one, two, or three to four of these adverse prognostic factors had five-year overall survival rates of 63, 53, 33, and 18 percent, respectively. [35]

References

  1. ↑ Morton, L. M. (2006). "Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001". Blood. 107 (1): 265–276. doi:10.1182/blood-2005-06-2508. ISSN 0006-4971.
  2. ↑ Moskowitz, A. J.; Lunning, M. A.; Horwitz, S. M. (2014). "How I treat the peripheral T-cell lymphomas". Blood. 123 (17): 2636–2644. doi:10.1182/blood-2013-12-516245. ISSN 0006-4971.
  3. ↑ . doi:10.1182/blood-2010-09-310342. Check |doi= value (help). Missing or empty |title= (help)
  4. ↑ "International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes". Journal of Clinical Oncology. 26 (25): 4124–4130. 2008. doi:10.1200/JCO.2008.16.4558. ISSN 0732-183X.
  5. ↑ Salaverria, Itziar; Beà, Silvia; Lopez-Guillermo, Armando; Lespinet, Virginia; Pinyol, Magda; Burkhardt, Birgit; Lamant, Laurence; Zettl, Andreas; Horsman, Doug; Gascoyne, Randy; Ott, German; Siebert, Reiner; Delsol, Georges; Campo, Elias (2008). "Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas". British Journal of Haematology. 140 (5): 516–526. doi:10.1111/j.1365-2141.2007.06924.x. ISSN 0007-1048.
  6. ↑ "International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes". Journal of Clinical Oncology. 26 (25): 4124–4130. 2008. doi:10.1200/JCO.2008.16.4558. ISSN 0732-183X.
  7. ↑ "International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes". Journal of Clinical Oncology. 26 (25): 4124–4130. 2008. doi:10.1200/JCO.2008.16.4558. ISSN 0732-183X.
  8. ↑ Geissinger, Eva; Odenwald, Tobias; Lee, Seung-Sook; Bonzheim, Irina; Roth, Sabine; Reimer, Peter; Wilhelm, Martin; M�ller-Hermelink, Hans Konrad; R�diger, Thomas (2004). "Nodal peripheral T-cell lymphomas and, in particular, their lymphoepithelioid (Lennert?s) variant are often derived from CD8+ cytotoxic T-cells". Virchows Archiv. 445 (4): 334–343. doi:10.1007/s00428-004-1077-2. ISSN 0945-6317. replacement character in |last8= at position 2 (help); replacement character in |last9= at position 2 (help)
  9. ↑ "International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes". Journal of Clinical Oncology. 26 (25): 4124–4130. 2008. doi:10.1200/JCO.2008.16.4558. ISSN 0732-183X.
  10. ↑ Charton-Bain MC, Brousset P, Bouabdallah R, Gaulard P, Merlio JP, Dubus P; et al. (2000). "Variation in the histological pattern of nodal involvement by gamma/delta T-cell lymphoma". Histopathology. 36 (3): 233–9. PMID 10692026.
  11. ↑ Zettl, Andreas; deLeeuw, Ron; Haralambieva, Eugenia; Mueller-Hermelink, Hans-Konrad (2007). "Enteropathy-Type T-Cell Lymphoma". American Journal of Clinical Pathology. 127 (5): 701–706. doi:10.1309/NW2BK1DXB0EQG55H. ISSN 0002-9173.
  12. ↑ Zettl, Andreas; Ott, German; Makulik, Angela; Katzenberger, Tiemo; Starostik, Petr; Eichler, Thorsten; Puppe, Bernhard; Bentz, Martin; Müller-Hermelink, Hans Konrad; Chott, Andreas (2002). "Chromosomal Gains at 9q Characterize Enteropathy-Type T-Cell Lymphoma". The American Journal of Pathology. 161 (5): 1635–1645. doi:10.1016/S0002-9440(10)64441-0. ISSN 0002-9440.
  13. ↑ Au, W.-y.; Weisenburger, D. D.; Intragumtornchai, T.; Nakamura, S.; Kim, W.-S.; Sng, I.; Vose, J.; Armitage, J. O.; Liang, R. (2008). "Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project". Blood. 113 (17): 3931–3937. doi:10.1182/blood-2008-10-185256. ISSN 0006-4971.
  14. ↑ Shapira, Michael Y.; Caspi, Ofer; Amir, Gail; Zlotogorski, Abraham; Naparstek, Yaakov (2009). "Gastric-Mucocutaneous γδ T Cell Lymphoma: Possible Association with Epstein-Barr Virus ?". Leukemia & Lymphoma. 35 (3–4): 397–401. doi:10.3109/10428199909145745. ISSN 1042-8194.
  15. ↑ Kanavaros, P.; Boulland, M. L.; Petit, B.; Arnulf, B. (2009). "Expression of Cytotoxic Proteins in Peripheral T-Cell and Natural Killer-Cell (NK) Lymphomas: Association with Extranodal Site, NK or Tγδ Phenotype, Anaplastic Morphology and CD30 Expression". Leukemia & Lymphoma. 38 (3–4): 317–326. doi:10.3109/10428190009087022. ISSN 1042-8194.
  16. ↑ Toro, J. R. (2003). "Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma". Blood. 101 (9): 3407–3412. doi:10.1182/blood-2002-05-1597. ISSN 0006-4971.
  17. ↑ Pizzi, Marco; Margolskee, Elizabeth; Inghirami, Giorgio (2018). "Pathogenesis of Peripheral T Cell Lymphoma". Annual Review of Pathology: Mechanisms of Disease. 13 (1): 293–320. doi:10.1146/annurev-pathol-020117-043821. ISSN 1553-4006.
  18. ↑ Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project (2008). "International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes". J Clin Oncol. 26 (25): 4124–30. doi:10.1200/JCO.2008.16.4558. PMID 18626005.
  19. ↑ Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA; et al. (2011). "Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project". Blood. 117 (12): 3402–8. doi:10.1182/blood-2010-09-310342. PMID 21270441.
  20. ↑ Falini B, Pileri S, De Solas I, Martelli MF, Mason DY, Delsol G; et al. (1990). "Peripheral T-cell lymphoma associated with hemophagocytic syndrome". Blood. 75 (2): 434–44. PMID 2153036.
  21. ↑ Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA; et al. (2011). "Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project". Blood. 117 (12): 3402–8. doi:10.1182/blood-2010-09-310342. PMID 21270441.
  22. ↑ Chott A, Dragosics B, Radaszkiewicz T (1992). "Peripheral T-cell lymphomas of the intestine". Am J Pathol. 141 (6): 1361–71. PMC 1886751. PMID 1466400.
  23. ↑ Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA; et al. (2011). "Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project". Blood. 117 (12): 3402–8. doi:10.1182/blood-2010-09-310342. PMID 21270441.
  24. ↑ Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R; et al. (2016). "The 2016 revision of the World Health Organization classification of lymphoid neoplasms". Blood. 127 (20): 2375–90. doi:10.1182/blood-2016-01-643569. PMC 4874220. PMID 26980727.
  25. ↑ Palomero T, Couronné L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A; et al. (2014). "Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas". Nat Genet. 46 (2): 166–70. doi:10.1038/ng.2873. PMC 3963408. PMID 24413734.
  26. ↑ Morton, L. M. (2006). "Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001". Blood. 107 (1): 265–276. doi:10.1182/blood-2005-06-2508. ISSN 0006-4971.
  27. ↑ Foss, F. M.; Zinzani, P. L.; Vose, J. M.; Gascoyne, R. D.; Rosen, S. T.; Tobinai, K. (2011). "Peripheral T-cell lymphoma". Blood. 117 (25): 6756–6767. doi:10.1182/blood-2010-05-231548. ISSN 0006-4971.
  28. ↑ Savage, K. J.; Harris, N. L.; Vose, J. M.; Ullrich, F.; Jaffe, E. S.; Connors, J. M.; Rimsza, L.; Pileri, S. A.; Chhanabhai, M.; Gascoyne, R. D.; Armitage, J. O.; Weisenburger, D. D. (2008). "ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project". Blood. 111 (12): 5496–5504. doi:10.1182/blood-2008-01-134270. ISSN 0006-4971.
  29. ↑ Foss, F. M.; Zinzani, P. L.; Vose, J. M.; Gascoyne, R. D.; Rosen, S. T.; Tobinai, K. (2011). "Peripheral T-cell lymphoma". Blood. 117 (25): 6756–6767. doi:10.1182/blood-2010-05-231548. ISSN 0006-4971.
  30. ↑ Lage, Luis Alberto de Pádua Covas; Cabral, Tamara Carvalho dos Santos; Costa, Renata de Oliveira; Gonçalves, Marianne de Castro; Levy, Debora; Zerbini, Maria Cláudia Nogueira; Pereira, Juliana (2015). "Primary nodal peripheral T-cell lymphomas: diagnosis and therapeutic considerations". Revista Brasileira de Hematologia e Hemoterapia. 37 (4): 277–284. doi:10.1016/j.bjhh.2015.03.017. ISSN 1516-8484.
  31. ↑ Moskowitz, A. J.; Lunning, M. A.; Horwitz, S. M. (2014). "How I treat the peripheral T-cell lymphomas". Blood. 123 (17): 2636–2644. doi:10.1182/blood-2013-12-516245. ISSN 0006-4971.
  32. ↑ Foss, F. M.; Zinzani, P. L.; Vose, J. M.; Gascoyne, R. D.; Rosen, S. T.; Tobinai, K. (2011). "Peripheral T-cell lymphoma". Blood. 117 (25): 6756–6767. doi:10.1182/blood-2010-05-231548. ISSN 0006-4971.
  33. ↑ Foss, F. M.; Zinzani, P. L.; Vose, J. M.; Gascoyne, R. D.; Rosen, S. T.; Tobinai, K. (2011). "Peripheral T-cell lymphoma". Blood. 117 (25): 6756–6767. doi:10.1182/blood-2010-05-231548. ISSN 0006-4971.
  34. ↑ Foss, F. M.; Zinzani, P. L.; Vose, J. M.; Gascoyne, R. D.; Rosen, S. T.; Tobinai, K. (2011). "Peripheral T-cell lymphoma". Blood. 117 (25): 6756–6767. doi:10.1182/blood-2010-05-231548. ISSN 0006-4971.
  35. ↑ Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U; et al. (2004). "Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study". Blood. 103 (7): 2474–9. doi:10.1182/blood-2003-09-3080. PMID 14645001.

Template:WS Template:WH

Retrieved from "https://www.wikidoc.org/index.php?title=Peripheral_T_cell_lymphoma&oldid=1505252"